These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37909622)
1. Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats. Ateş Ç; Dilbaz B; Ergani SY; Atabay F Rev Assoc Med Bras (1992); 2023; 69(11):e20230789. PubMed ID: 37909622 [TBL] [Abstract][Full Text] [Related]
2. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116 [TBL] [Abstract][Full Text] [Related]
3. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model. Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356 [TBL] [Abstract][Full Text] [Related]
5. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model? Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121 [TBL] [Abstract][Full Text] [Related]
6. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study. Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome. Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961 [TBL] [Abstract][Full Text] [Related]
8. Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome? Yilmaz N; Gulsen Coban P; Yilmaz S; Inal HA; Timur H; Haltas H Gynecol Endocrinol; 2023 Dec; 39(1):2217295. PubMed ID: 37247633 [TBL] [Abstract][Full Text] [Related]
9. Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome? Çilgin H Drug Des Devel Ther; 2019; 13():1099-1105. PubMed ID: 31040646 [TBL] [Abstract][Full Text] [Related]
10. Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186 [TBL] [Abstract][Full Text] [Related]
12. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279 [TBL] [Abstract][Full Text] [Related]
13. Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405 [TBL] [Abstract][Full Text] [Related]
14. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome. Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469 [TBL] [Abstract][Full Text] [Related]
15. Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model. Kasap E; Turan GA; Eskicioğlu F; Cengiz H; Gur EB; Sivrikoz ON; Genc M; Yılmaz O Gynecol Endocrinol; 2016 Aug; 32(8):634-640. PubMed ID: 26939766 [TBL] [Abstract][Full Text] [Related]
16. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model. Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170 [TBL] [Abstract][Full Text] [Related]
17. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. Gaafar S; El-Gezary D; El Maghraby HA Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458 [TBL] [Abstract][Full Text] [Related]
18. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964 [TBL] [Abstract][Full Text] [Related]
19. Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin. Mills G; Dahan MH Arch Gynecol Obstet; 2022 Nov; 306(5):1731-1737. PubMed ID: 35932297 [TBL] [Abstract][Full Text] [Related]
20. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]